PRELIMINARY RESULTS OF A PROSPECTIVE, SINGLE CENTER, RANDOMIZED CONTROLLED STUDY ON FEASIBILITY, SAFETY AND EFFICACY OF THREE DIFFERENT TECHNIQUES OF ENDOSCOPIC GASTROPLASTY

Le résumé fourni par la source

Aims Endoscopic Gastroplasty (EG) is an endoscopic therapy focusing on gastric body remodeling to treat mostly I and II grade of obese patients. Our study aimed to assess feasibility, safety, and efficacy of endoscopic sleeve gastroplasty (ESG), endoluminal vertical gastroplasty (EVG), and distal primary obesity surgery endoluminal (D-POSE). Methods This was a prospective, single center, randomized controlled study (ClinicalTrials.gov NCT04854317) of patients who underwent EG through ESG or EVG or D-POSE for the treatment of obesity. Outcomes included technical success rate, serious adverse event rate, and efficacy of these three procedures at inducing weight loss, improving obesity-related comorbidities and quality of life. Results Between July 2020 and April 2021, 54 obese (body mass index 37.1±2.9 kg/m ) patients (mean age, 45±10 years; sex, female 51 (94.4%); baseline comorbidities in [ Table 1 ]) underwent EG through ESG or EVG or D-POSE ([ Figure 1 ], respectively). The technical success rate was 100%. The stomach was shortened by 11.4±4.2 cm, representing a 35.5% reduction. The serious adverse event rate was 0%. At 6 months, patients experienced 15.5%±5.1% total body weight loss. Fifty-three (98.1%) patients achieved at least 5% total body weight loss, and 46 patients (85.2%) achieved at least 25% excess weight loss. Fatty liver disease, hypertension, hyperlipidemia, diabetes, and obstructive sleep apnea improved after the procedure. Also the quality of life measured by BAROS test improved at 6-month follow-up (p<0.01). Fig. 1 Table 1 Fatty Liver disease 38 (70.0%) Hypertension 14 (25.9%) Hyperlipidemia 9 (16.7%) Obstructive sleep apnea 8 (14.8%) Type 2 diabetes mellitus/GERD 6 (11.1%) Conclusions Endoscopic Gastroplasty through ESG, EVG and D-POSE, focusing on gastric body reduction are technically feasible, safe and effective for treatment of obese patients. Publication History Article published online: 14 April 2022 © 2022. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.